Vascular procedure denied? We cite SVS, ACC/AHA, and the trial data they ignored.

Why vascular denials hinge on size, classification, and IFU

Vascular and endovascular procedures are some of the most quantitatively precise in all of medicine. An aneurysm is a number in centimeters. A carotid stenosis is a NASCET percentage. A PAD case is a Rutherford class plus an ABI plus a TBI. A varicose vein is a CEAP class plus a duplex reflux duration. An endograft is a list of FDA-IFU parameters that either match the patient's anatomy or do not.

Insurers know this — and their denial workflows are built around the question, "Did the chart actually contain the measurement, or are we paying for an opinion?" When a vascular denial arrives, the appeal almost always reduces to (a) producing the measurement, (b) citing the SVS guideline that endorses the threshold, and (c) demonstrating the device IFU compliance.

The good news is the Society for Vascular Surgery publishes detailed, evidence-graded clinical practice guidelines for every common vascular denial scenario, and most insurer policies cite SVS verbatim. The work of a vascular appeal is not invention — it is matching the chart documentation to the SVS or ACC/AHA language the insurer's own policy already references.

The five denial categories you will actually see

Most vascular denials reduce to five rejections:

1. "AAA below 5.5 cm — surveil instead" — for elective AAA repair, the SVS 2018 threshold is 5.5 cm in men and 5.0 cm in women, with sub-threshold repair justified by rapid growth (≥0.5 cm in 6 months), saccular morphology, or symptomatic / tender presentation.

2. "Carotid stenting investigational / CEA preferred" — for carotid revascularization, the choice between CEA, transfemoral CAS, and TCAR depends on symptom status, NASCET stenosis, and high-risk anatomy or comorbidity.

3. "PAD: try exercise and medications first" — for claudication, supervised exercise plus optimized medical therapy is required. For CLTI, Rutherford 4–6 with WIfI staging and ABI/TBI/TcPO2 documentation is the gateway.

4. "Varicose veins are cosmetic" — for endovenous ablation, CEAP ≥C2 with symptoms, duplex reflux >0.5 s, vein diameter ≥3 mm, and failed compression therapy is the standard threshold.

5. "IVC filter not medically necessary" — for IVC filter, anticoagulation contraindication or failure plus VTE event is the requirement, with a documented retrieval plan if retrievable.

Each of these has a precise SVS, ACC/AHA, or pivotal-trial counter, and the appeal letter writes itself once the chart is complete.

AAA repair: SVS 2018, IFU, and the size threshold debate

The 2018 SVS Clinical Practice Guideline on AAA (Chaikof, J Vasc Surg 2018;67(1):2–77) is the controlling document. It endorses ≥5.5 cm in men and ≥5.0 cm in women as the threshold for elective AAA repair, supported by the UK Small Aneurysm Trial (NEJM 2002) and ADAM (Lederle NEJM 2002), which both showed no rupture-prevention benefit from earlier intervention in average-risk patients. Sub-threshold repair is supported by:

• Rapid growth (≥0.5 cm in 6 months or ≥1 cm in 1 year).
• Saccular morphology, which has higher rupture risk per diameter than fusiform.
• Symptomatic or tender presentation.
• Family history with strong rupture pattern, particularly in women.

For EVAR specifically, the appeal must address FDA IFU compliance. The CTA planning report needs to explicitly compare the patient's anatomy to the device IFU for each parameter:

• Infrarenal neck length (typically ≥10 mm for most devices, ≥15 mm for older platforms).
• Neck angulation (typically <60°, sometimes <75° for the Cook Zenith Alpha).
• Neck thrombus and calcium burden.
• Common iliac diameters (typically 8–24 mm depending on device).
• Suprarenal angle for some platforms.

When the patient is outside standard EVAR IFU, the appeal pivots to fenestrated or branched EVAR (F-EVAR / B-EVAR) with the same anatomic justification. Cite the IDE or post-market data on the specific device (Cook Zenith Fenestrated, Gore TAMBE, etc.) and SVS supplementary guidance.

The mortality data — DREAM (Prinssen NEJM 2004), EVAR-1 (Greenhalgh NEJM 2010 long-term), OVER (Lederle NEJM 2012) — establishes EVAR's 30-day perioperative mortality benefit over open repair. For high-comorbidity patients, this is the central argument.

Carotid revascularization: CREST changed the landscape, but symptom status still drives

The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST, Brott NEJM 2010 with 10-year follow-up Brott NEJM 2016) is the central document for any CEA-versus-CAS decision. CREST showed comparable combined endpoints (stroke, MI, death) at 10 years, with CAS having higher peri-procedural stroke and CEA having higher peri-procedural MI. The 2022 SVS Carotid Guideline (AbuRahma JVS 2022) integrates CREST with EVA-3S, ICSS, ACT-1, SPACE-2, and ROADSTER 2.

A successful carotid revascularization appeal includes:

• The carotid duplex report with peak systolic velocity, end-diastolic velocity, ICA/CCA ratio, and the NASCET-equivalent stenosis percentage.
• Symptom documentation — TIA or stroke event date, side, neurologic symptoms, MRI/MRA correlation, NIHSS at presentation.
• For asymptomatic disease, life-expectancy and risk-factor profile (PHASES-style framework).
• For CAS or TCAR specifically, documentation of high surgical risk for CEA (radical neck dissection, prior neck radiation, contralateral laryngeal nerve palsy, contralateral occlusion, restenosis post-CEA, severe cardiac/pulmonary comorbidity).
• For TCAR specifically, cite ROADSTER 2 (Kashyap JVS 2020) and the FDA approval for the Silk Road Medical ENROUTE system.

CMS NCD 20.7 covers carotid stenting for symptomatic ≥50% stenosis in high-risk patients and asymptomatic ≥70% in selected high-risk patients with reasonable life expectancy. Mirror the NCD line items in the appeal.

Peripheral arterial disease: 2024 multisociety guideline raised the bar

The 2024 ACC/AHA/SVS Multisociety Lower Extremity PAD Guideline (Gornik Circulation 2024) is now the controlling document. It endorses optimized medical therapy (statin, antiplatelet, ACE-I or ARB, smoking cessation, supervised exercise) as first-line for claudication, with revascularization reserved for lifestyle-limiting symptoms refractory to ≥12 weeks of optimized therapy. For CLTI (Rutherford 4–6), revascularization is supported earlier with WIfI staging.

For the claudication denial, the appeal must include:

• A supervised exercise therapy log — ≥12 weeks, with sessions per week, claudication distance pre/post, and adherence.
• Statin (typically high-intensity, atorvastatin 40–80 or rosuvastatin 20–40), with LDL response.
• Antiplatelet — aspirin or clopidogrel (or both per COMPASS for higher-risk patients).
• ACE-I or ARB.
• Smoking cessation documentation with months tobacco-free.
• Cilostazol trial in eligible patients (no HF, no concomitant CYP-3A4 inhibitors).
• The Rutherford classification, ABI / TBI, and functional impact (walking distance, occupation, quality of life).

For CLTI, the appeal includes the WIfI staging (W = wound, I = ischemia, fI = foot infection), explicit measurements (ABI, TBI, TcPO2, skin perfusion pressure), and the SVS Global Vascular Guidelines (Conte JVS 2019). The BEST-CLI trial (Farber NEJM 2022) is the most important recent data — bypass with single-segment greater saphenous vein outperformed endovascular in the primary cohort, but endovascular is appropriate when GSV is not available or when anatomy / comorbidity favors it. BASIL (Adam Lancet 2005) and BASIL-2 / BASIL-3 provide additional context.

For atherectomy, document calcium burden on imaging and the rationale for atherectomy versus angioplasty / DCB / DES. For drug-coated balloons below the knee, cite IN.PACT DEEP and DEBATE-BTK with appropriate caveats.

Varicose veins: CEAP, reflux, and the cosmetic question

Almost every varicose vein denial says "cosmetic." The defense is to document the C in CEAP, the duplex reflux, and the failed compression therapy.

A successful endovenous ablation appeal includes:

• The full CEAP classification (C = clinical, E = etiology, A = anatomy, P = pathophysiology). For coverage, CEAP ≥C2 with symptoms is the floor.
• The Venous Clinical Severity Score (VCSS), a validated symptom-quantification tool.
• A duplex ultrasound report with reflux duration in seconds in the target truncal vein (GSV, SSV, anterior accessory) and vein diameter at the saphenofemoral or saphenopopliteal junction. Reflux >0.5 s and diameter ≥3 mm are the standard thresholds.
• Symptom documentation — pain, heaviness, swelling, fatigue, night cramps, restless legs, or actual skin changes.
• A compression therapy log — typically 20–30 mmHg medical-grade compression, ≥6–12 weeks, with adherence and outcome.

Cite the SVS / AVF Clinical Practice Guidelines on Varicose Veins (Gloviczki JVS 2011 + 2024 update) and the AAO-style joint multispecialty positions. For VenaSeal and ClariVein specifically, cite VeClose (Morrison JVS 2015) for VenaSeal vs RFA and the FDA clearances (VenaSeal 2015, ClariVein 2008).

For CEAP C4–C6 (skin changes, healed venous ulcer, active venous ulcer), the EVRA trial (Gohel NEJM 2018) showed that early endovenous ablation accelerates ulcer healing and reduces recurrence. C4–C6 cases are rarely deniable when documentation is complete.

For sclerotherapy, distinguish ultrasound-guided foam sclerotherapy of truncal veins or large tributaries (covered when criteria are met) from cosmetic spider-vein sclerotherapy of telangiectasias (typically not covered). The chart and CPT must reflect the difference.

IVC filters: the indication is everything

IVC filter denials are common because the procedure is one of the most over-utilized in vascular medicine, and insurers know it. The defense is a tight indication narrative.

A successful IVC filter appeal documents one of:

• Acute VTE (DVT or PE) with absolute anticoagulation contraindication — active major bleeding, recent neurosurgery or spine surgery, intracranial hemorrhage, severe thrombocytopenia.
• Acute VTE with anticoagulation failure — recurrent PE despite therapeutic INR or anti-Xa documentation.
• Selected high-risk surgical or trauma patients per SVS / ACCP guidance, with a clear anticipated AC contraindication.

For retrievable filters, document a retrieval plan in the chart with a target date (typically within 30–90 days of placement, certainly within the device's labeled retrieval window). Cite the SVS Reporting Standards for IVC Filter and the PRESERVE Registry outcomes. The FDA 2010 and 2014 safety communications on retrievable IVC filters reinforce the importance of retrieval plans.

Filter retrieval is rarely denied when the original placement was documented and the retrieval window is appropriate.

DVT catheter-directed thrombolysis: ATTRACT was complicated, but iliofemoral matters

ATTRACT (Vedantham NEJM 2017) was the largest randomized trial of pharmacomechanical thrombolysis versus anticoagulation alone for proximal DVT. The overall result was null for post-thrombotic syndrome at 24 months — but the iliofemoral subgroup showed reduced PTS severity and the femoropopliteal subgroup did not. CaVenT (Enden Lancet 2012, 5-year Haig Lancet Haematol 2016) showed reduced PTS at 5 years with catheter-directed thrombolysis.

A successful DVT thrombolysis appeal documents:

• Acute proximal (iliofemoral) DVT on duplex with explicit anatomic level.
• Severe symptoms — phlegmasia cerulea / alba dolens, limb-threatening venous ischemia, severe pain and edema.
• Low bleeding risk — no recent surgery, no bleeding diathesis, age and renal function appropriate for thrombolytic agent.
• Functional status — young, active patient with high lifetime PTS burden.
• The SVS / ACCP guidance on selected catheter-directed thrombolysis for severe iliofemoral DVT.

Hemodialysis vascular access: KDOQI Fistula First

For AVF or AVG creation in ESRD, the controlling document is the 2020 KDOQI Vascular Access Guideline (Lok AJKD 2020), which moved past the rigid "Fistula First" framework toward a "patient-centered ESKD Life Plan." Most insurers still mirror the older Fistula First language.

A successful AVF / AVG appeal documents:

• ESRD diagnosis with eGFR and dialysis dependence.
• Vascular mapping (vein and artery diameters on duplex) confirming candidacy.
• A planned access strategy — AVF preferred over AVG, AVG preferred over CVC, with rationale.
• The KDOQI 2020 Life Plan reference.
• For high-risk patients (elderly, poor vasculature), document why AVG or alternative access is more appropriate than AVF.

TEVAR and thoracic aortic disease

For thoracic endovascular aortic repair, the indications include:

• Descending thoracic aortic aneurysm typically ≥5.5 cm or rapidly expanding.
• Type B aortic dissection with complications (malperfusion, rupture, refractory pain, refractory hypertension).
• Traumatic blunt aortic injury (BAI) per SVS guidelines.
• Aortic transection or contained rupture.

The appeal cites the SVS thoracic aortic guidelines, the INSTEAD-XL data (Nienaber Circulation 2013) for uncomplicated Type B at intermediate-term, and the ADSORB data. FDA IFU compliance for the specific TEVAR device (Gore TAG, Medtronic Valiant, Cook Zenith TX2) is central.

The peer-to-peer call: same-specialty matters

Most vascular denials carry a 14-day peer-to-peer window. Demand a same-specialty reviewer — a vascular surgeon, not a cardiologist or radiologist (although vascular-trained interventional cardiologists or interventional radiologists are acceptable for endovascular cases). Bring the imaging measurements, the medical-therapy log, and the SVS guideline citation that the insurer's own policy mirrors.

The peer-to-peer overturns more vascular denials than any other appeal mechanism, because the medical director is often a generalist who is not familiar with the specific anatomic and classification language.

A note on letter length and structure

A vascular appeal should be 1.5 to 2 pages. The structure that works:

1. Header with member ID, claim number, procedure, CPT.

2. Diagnosis with ICD-10, duration, and the anchoring measurement (AAA diameter, NASCET stenosis, Rutherford class with ABI, CEAP class with reflux duration).

3. Conservative therapy / medical therapy log — concise but complete.

4. Anatomic / IFU suitability — for any endograft case, IFU compliance.

5. Address the denial directly — quote the insurer's own coverage criteria, demonstrate each is met, cite SVS / ACC-AHA / pivotal trial.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty vascular surgeon.

Tone is professional, firm, evidence-driven. Let the millimeter, the percentage, the Rutherford class, and the SVS reference do the work.

When to escalate

Self-funded ERISA plans go through second-level internal appeal then external review under ACA §2719. Fully-insured state-regulated plans go through state external review. Medicare Advantage cases route through the Independent Review Entity (IRE) and the ALJ hearing. Medicaid follows the state Fair Hearing process. Each level has its own deadlines (typically 60–180 days from the prior denial).

Most vascular denials reverse on first appeal when SVS or ACC/AHA is cited, the chart documentation matches the policy criteria, and the peer-to-peer is requested. The work is in the documentation — once the chart contains the right measurements and the right references, drafting the letter is mechanical.